✔ 100% Authentic Product
Bortez 2mg Injection
Bortez is a proteasome inhibitor indicated for:
- Treatment of adult patients with multiple myeloma
- Treatment of adult patients with mantle cell lymphoma
Take this medication only as directed by a registered physician.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Cashback offer (Optional):
🔹 Foreign manufacturer products are not applicable for Cashback offer
Cash on Delivery - All over Bangladesh
Urgent Delivery - 2 Hours Dhaka City
ফ্রি ডেলিভারি! - ১৪৯৯ টাকা+ অর্ডারে ঢাকা
শহরে ।- ফ্রি ডেলিভারি! - ২৯৯৯ টাকা+ অর্ডারে ঢাকার
বাহিরে ।
✅ Description:
Bortezomib is an antineoplastic drug available for intravenous (IV) and subcutaneous injection. It acts as a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex responsible for degrading ubiquitinated proteins, crucial for regulating specific intracellular proteins and maintaining cellular homeostasis. Inhibition of this pathway disrupts normal cellular processes and can lead to cell death. Studies have shown that Bortezomib is cytotoxic to various cancer cell types and delays tumor growth in models of multiple myeloma.
The distribution volume of Bortezomib at the recommended dose in patients with multiple myeloma has not been assessed. The average binding of Bortezomib to human plasma proteins is 83% within the concentration range of 100–1000 ng/mL.
Bortezomib is primarily metabolized via cytochrome P450 enzymes (3A4, 2C19, and 1A2), with minor metabolism through CYP 2D6 and 2C9. The major metabolic route involves deboronation, resulting in two de-boronated metabolites, which are inactive as proteasome inhibitors.
The mean elimination half-life of Bortezomib ranges from 9 to 15 hours, with doses between 1.45 and 2.00 mg/m2 in patients with advanced cancers. The elimination pathways of Bortezomib in humans have not been fully characterized.
✔️ Possible side effects during treatment with Bortez include:
- Peripheral Neuropathy
- Hypotension
- Cardiac Toxicity
- Pulmonary Toxicity
- Posterior Reversible Encephalopathy Syndrome (PRES)
- Gastrointestinal Toxicity
- Thrombocytopenia/Neutropenia
- Tumor Lysis Syndrome
- Hepatic Toxicity
✔️ Dosage & Administration of Bortez 2mg Injection
The recommended dose of Bortezomib is 1.3 mg/m2 per dose administered intravenously or subcutaneously as a 3 to 5-second bolus twice weekly for 2 weeks (Days 1, 4, 8, and 11), followed by a 10-day rest period (Days 12-21). For extended therapy beyond 8 cycles, Bortezomib may be administered weekly for 4 weeks (Days 1, 8, 15, and 22), followed by a 13-day rest period (Days 23-35).
Retreatment may be considered for patients who responded previously to Bortezomib and relapsed at least 6 months after prior treatment. The dose may be started at the last tolerated dose. Bortezomib is for intravenous or subcutaneous use only.
- Renal Impairment: No dose adjustment is necessary for patients with renal impairment.
- Pediatric Use: Safety and efficacy in children have not been established.
- Diabetes: Close monitoring of blood glucose levels is advised for diabetic patients.
Take this medication only as directed by a registered physician.
✔️ Interaction
No formal drug interaction studies have been conducted with Bortez. However, in vitro studies suggest Bortez is primarily a substrate of cytochrome P450 3A4, 2C19, and 1A2. It may inhibit the activity of 2C19 and increase exposure to drugs metabolized by this enzyme. Bortez is a poor inhibitor of several other cytochrome P450 enzymes.
✔️ Contraindications
Bortezomib is contraindicated in patients with hypersensitivity to Bortezomib, boron, or mannitol, and for intrathecal administration, as fatal reactions have occurred.
✔️ Overdose Effects
Overdosage may lead to symptomatic hypotension and thrombocytopenia with fatal outcomes. In the case of an overdose, monitor vital signs and provide supportive care.
✔️ Pregnancy & Lactation
Pregnancy Category D. Women of childbearing potential should avoid pregnancy during Bortezomib treatment. No studies have been conducted to assess placental transfer. Bortezomib may pose a risk to the fetus if used during pregnancy.
✔️ Precautions & Warnings
- Peripheral Neuropathy: Patients may experience worsening symptoms, including sensory or motor neuropathy. Dose adjustments may be required.
- Hypotension: Exercise caution in patients with a history of syncope or those taking medications that lower blood pressure.
- Cardiac Disorders: Monitor closely for heart failure or QT interval prolongation.
- Gastrointestinal Issues: Nausea, diarrhea, constipation, and vomiting are common; supportive treatments may be required.
- Pulmonary Toxicity: Acute respiratory conditions like ARDS, pneumonitis, and interstitial pneumonia may occur.
- Thrombocytopenia/Neutropenia: Monitor blood counts and adjust treatment as necessary.
- Tumor Lysis Syndrome: Close monitoring is necessary for patients with high tumor burden.
- Hepatic Toxicity: Monitor liver function and assess any acute liver issues.
✔️ Storage Conditions
- Unopened vial: Store below 25°C and protect from light.
- Reconstituted solution: Store between 2°C-8°C and use within 8 hours. Do not use if the solution is discolored or contains particulate matter.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.
